Robust & reliable neoantigen prediction to empower the next generation cancer immunotherapies.
NEC OncoImmunity AS is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona fide immunogenic neoantigens for personalized cancer immunotherapy.
NEC OncoImmunity AS is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in a clinically actionable time-frame.
NEC OncoImmunity AS is a subsidiary of NEC Corporation, and is based in Oslo, Norway.
NEC OncoImmunity AS has assembled a growing and experienced multidisciplinary team of bioinformaticians, software-engineers and data scientists with machine-learning expertise.
A development environment deeply immersed in the combined scientific fields of bioinformatics, biotechnology, onco-immunology and data science